http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010296180-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a82962e22b6ae66d43ee1e8c950d93db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c269250445f394b12b0f07ce1374d33
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2982
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
filingDate 2010-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd50879f0b10c74b56dfbf39a3105d4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f734f6746f36a8e762b06b1f20fda99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b8a4a07b15ba2f1a5916260f7aa0888
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb711310117a7e2b4dfd96e7f7348831
publicationDate 2012-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2010296180-A1
titleOfInvention Oxaliplatin nanoparticles and method for preparing same
abstract The present invention relates to oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, to a pharmaceutical composition comprising the nanoparticles, and to a method which involves emulsifying a lipid mixture solution, in which solid lipids and a surfactant are mixed, into an aqueous mixture solution in which oxaliplatin and a specific cosolvent are mixed, and removing the solid lipids and the cosolvent using supercritical fluid gas, to thereby prepare orally administrable nanoscale oxaliplatin particles. The oxaliplatin nanoparticles and method for preparing same according to the present invention are advantageous in that oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, can be prepared in an economic manner using a supercritical fluid production facility which is relatively inexpensive, and oxaliplatin nanoparticles can be prepared with a high recovery factor through a simple process and can be easily commercialized. In addition, oxaliplatin, which has been thus-far prepared as injectable formulations, is prepared into nanoparticles to enable the development of oxaliplatin oral formulations which are safe to stomach acids and which have improved bioavailability, thereby preventing inconveniences and problems in using injectable formulations, and significantly contributing to the improvement of patient compliance and a reduction in medical expenses.
priorityDate 2009-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530516
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID137231040
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505489
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID43806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415133005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID479307
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419583148
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91825658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136170999
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105166
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419583147
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450144521
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6857599
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454411087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420327631
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135403648
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426284263

Total number of triples: 51.